Substituted 6,5-fused bicyclic heteroaryl compounds

Patent metadata

Field	Value
Publication number	US-10273223-B2
Application number	US-201715492506-A
Country	US
Kind code	B2
Filing date	Apr 20, 2017
Priority date	Feb 28, 2011
Publication date	Apr 30, 2019
Grant date	Apr 30, 2019

Abstract

The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.

First claim

What is claimed is:

1. A compound of Formula (lb) or a pharmaceutically acceptable salt thereof:

wherein:
X 2 is N or CH;
X 3 is CR 8 ;
X 4 is C;
Y 1 is CH;
Y 3 is CR 11 ;
R 6 is phenyl or a 5 to 6-membered heteroaryl selected from the group consisting of pyridinyl, pyrazolyl, pyrimidinyl, and furyl, wherein the phenyl and 5 to 6-membered heteroaryl are substituted with one or more -Q 2 -T 2, in which Q 2 is a bond, and T 2 is unsubstituted 4 to 7-membered heterocycloalkyl;
R 7 is C 1 -C 6 alkyl or cyclopentyl;
each of R 8 independently is H or methyl or ethyl; and
R 11 is H.

2. The compound of claim 1 , wherein R 6 is pyridinyl optionally substituted with one or more -Q 2 -T 2 .

3. The compound of claim 2 , wherein X 2 is CH.

4. The compound of claim 2 , wherein T 2 is azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, or morpholinyl.

5. The compound of claim 4 , wherein T 2 is piperazinyl.

6. The compound of claim 5 , wherein R 7 is methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl, or n-hexyl.

7. The compound of claim 6 , wherein R 7 is s-butyl.

8. The compound of claim 5 , wherein R 11 is H.

9. The compound of claim 8 , wherein R 8 is methyl.

10. The compound of claim 9 , wherein the compound has R configuration.

11. The compound of claim 9 , wherein the compound has S configuration.

12. A compound of Formula (lb) or a pharmaceutically acceptable salt thereof:

wherein:
X 2 is CH;
X 3 is CR 8 ;
X 4 is C;
Y 1 is CH;
Y 3 is CR 11 ;
R 6 is pyridinyl substituted with one or more -Q 2 -T 2 , in which Q 2 is a bond, and T 2 is piperazinyl;
R 7 is s-butyl;
R 8 is methyl;
R 11 is H, and
wherein the compound has S configuration.

13. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Assignees

• Epizyme Inc

Inventors

• Kuntz Kevin Wayne
• Olhava Edward James
• Chesworth Richard
• Duncan Kenneth William

Classifications

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D471/04

  Ortho-condensed systems · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• C07D401/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title